Mutagentech
Private Company
Funding information not available
Overview
Mutagentech, founded in 2018, is a private diagnostics company commercializing a proprietary sequencing platform called SMM-seq™. This technology uses rolling circle amplification to detect rare somatic mutations and structural variants with high accuracy, addressing a major challenge in studying genome instability in aging and disease. Led by a scientifically distinguished founding team, the company currently offers sequencing services directly to researchers and is in a pre-revenue or early-revenue stage, targeting the research tools and clinical diagnostics markets.
Technology Platform
Single Molecule Mutation Sequencing (SMM-seq™), a sequencing platform using rolling circle amplification (RCA) and consensus calling to detect ultra-rare somatic point mutations and structural variants with high sensitivity (down to 1x10^-5 to 1x10^-6 frequency).
Opportunities
Risk Factors
Competitive Landscape
Mutagentech competes in the high-sensitivity sequencing space with large diagnostics firms (e.g., Guardant Health, Natera, Illumina) offering liquid biopsy MRD tests, as well as other specialized startups. Its differentiation lies in its unique RCA-based wet-lab method for error suppression, as opposed to primarily computational error-correction approaches used by others.